Studies on alpha-adrenergic activation of hepatic glucose output.
D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / Q000494:pharmacology; D000322:Adrenergic Agonists / Q000494:pharmacology*; D000818:Animals; D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D004837:Epinephrine / Q000494:pharmacology; D005934:Glucagon / Q000494:pharmacology; D005943:Gluconeogenesis / Q000187:drug effects*; D005947:Glucose / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D010643:Phenoxybenzamine / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011770:Pyruvate Kinase / Q000037:antagonists & inhibitors*; D051381:Rats; D014667:Vasopressins / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology
D000322:Adrenergic Agonists; D014970:Xanthines; D010643:Phenoxybenzamine; D014667:Vasopressins; D010656:Phenylephrine; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; D000001:Calcimycin; D005934:Glucagon; D011433:Propranolol; D011770:Pyruvate Kinase; D005947:Glucose; D002118:Calcium; D004837:Epinephrine